How India’s Torrent Is Building Resilience In Brazil
This article was originally published in PharmAsia News
India’s Torrent Pharmaceuticals reported a strong set of numbers for the third quarter ended December 2015 despite turbulence in markets like Brazil, where it has done some sharp "belt tightening" but remains bullish over the long term.
You may also be interested in...
Price gains and a regulator that has turned more responsive appear to be among the key factors contributing to the improving sentiment in Brazil for India's Torrent even as the South American nation tackles intense political and economic turbulence. While Torrent reported a sharp decline in its earnings in the first quarter largely due to exceptional gains in the comparable previous period, its Brazilian business is looking up.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."